Marksans Pharma UK arm gets MHRA nod for Mefenamic Acid Film-Coated Tablets
Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary, Relonchem Limited in UK, has received Marketing Authorization for its two products from UK Medicines and Healthcare products Regulatory Agency (MHRA).
The authorization covers Mefenamic Acid Film-Coated Tablets in 250 mg and 500 mg strengths.
This approval adds to a series of UK MHRA authorizations Relonchem has secured throughout the year.
Earlier this month, the company received approval for Exemestane 25mg film-coated tablets from UK MHRA.
In October, Relonchem obtained Marketing Authorization for Clonidine 100 microgram Tablets and Clonidine Hydrochloride 25 microgram Tablets from UK MHRA.
In September, the UK arm also received UK MHRA approval for Moxonidine 200 microgram Tablets and Moxonidine 400 microgram Tablets.
In August, Relonchem received marketing authorisation for three strengths of its Metformin Hydrochloride Relonchem Prolonged Release Tablets.
In June 2025, the subsidiary secured marketing authorization for Oxybutynin hydrochloride 2.5mg/5ml Oral Solution.
In late May, Relonchem received marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution, followed by approval for Sennosides 7.5 mg Tablets earlier in the month.
In March, the UK MHRA approved Baclofen 10 mg Tablets, a medication used to relax specific muscles in the body, relieving spasms, cramps, and tightness associated with multiple sclerosis or spinal injuries.
The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK.
Back in February, Relonchem also received authorization for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets (Bell's Healthcare Dual Action Pain Relief 200 mg/500 mg Film-coated Tablets).
